Large-vessel vasculitis (LVV) manifests as inflammation of the aorta and its major branches
and is the most common primary vasculitis in adults. LVV comprises two distinct conditions …

Glucocorticoids (GCs) have been the cornerstone of treating dozens of inflammatory
conditions for more than seven decades. GC toxicity is ubiquitous in both clinical trials and …

Background Since the publication of the European League Against Rheumatism (EULAR)
recommendations for the management of large vessel vasculitis (LVV) in 2009, several …

GCA is the most common form of primary systemic vasculitis affecting older people. It is
considered a clinical emergency because it can lead to irreversible blindness in around …

Abstract The coronavirus disease 2019 (COVID-19) pandemic is concerning for patients with
neuroimmunological diseases who are receiving immunotherapy. Uncertainty remains …

Objectives Clinical presentations of giant cell arteritis (GCA) are protean, and it is vital to
make a secure diagnosis and exclude mimics for urgent referrals with suspected GCA. The …

Objective Tocilizumab plus prednisone induces sustained glucocorticoid-free remission in
patients with GCA. However, its long-term benefits in new-onset vs relapsing disease are …

Background Placebo-controlled clinical trials have demonstrated the efficacy of tocilizumab
(TCZ) for remission maintenance and glucocorticoid sparing in patients with giant cell …

Background Targeting interleukin (IL)-6 has become a major therapeutic strategy in the
treatment of immune-mediated inflammatory disease. Interference with the IL-6 pathway can …

Background Effective and safe therapies are needed for the treatment of patients with giant
cell arteritis (GCA). Emerging as a key cytokine in inflammation, granulocyte-macrophage …